New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Lilly's valuation seems reasonable given its growth prospects. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY ...

Explore the growth potential of the Alzheimer's disease-modifying therapies (DMTs) market as lecanemab gains FDA approval in 2023. With several late-stage trials underway, anticipate market shifts ...

Early dementia signs can resemble the normal cognitive changes of aging. But timely diagnosis can help people get the ...

Shares of Vertex Pharmaceuticals plunged more than 14% to $404.89 after it release disappointing top-line results from its recently completed Phase II, randomized, double-blind, placebo-controlled ...

Biosimilars, once met with skepticism, are now an undeniable force in the global pharmaceutical market. As several ...